Optimize Meds for Comorbidities in Nonalcoholic Fatty Liver Disease
September 2017
You'll see more attention paid to the management of nonalcoholic fatty liver disease (NAFLD)...as it becomes more common.
Up to 100 million Americans have this buildup of fat in the liver...usually without any symptoms. It often goes hand in hand with obesity, dyslipidemia, insulin resistance, and diabetes.
About 20% of patients with NAFLD have nonalcoholic steatohepatitis (NASH)...the more severe form with inflammation and sometimes fibrosis.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote